ABIVAX Société Anonyme/€ABVX
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About ABIVAX Société Anonyme
Abivax Société Anonyme is a clinical-stage biotechnology company headquartered in Paris, France, with a research center in Montpellier and a U.S. office in Waltham, Massachusetts. Founded in December 2013, the company focuses on developing therapeutics that modulate the immune response to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod (formerly ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis and is being prepared for a Phase 2a trial in Crohn's disease. Abivax collaborates closely with the French National Center for Scientific Research (CNRS), the Institut Curie, and the University of Montpellier. In 2015, the company raised €57.7 million in its initial public offering on Euronext Paris, and in October 2023, it raised €232.3 million through an IPO on the Nasdaq Global Market.
Ticker
€ABVX
Sector
Primary listing
PAR
Employees
67
Headquarters
Website
ABVX Metrics
BasicAdvanced
€7.5B
-
-€4.46
-0.25
-
Price and volume
Market cap
€7.5B
Beta
-0.25
52-week high
€130.80
52-week low
€4.51
Average daily volume
21K
Financial strength
Current ratio
7.863
Quick ratio
7.737
Long term debt to equity
8.722
Total debt to equity
14.472
Interest coverage (TTM)
-14.95%
Profitability
EBITDA (TTM)
-217.953
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-5,526.64%
Operating margin (TTM)
-4,123.61%
Revenue per employee (TTM)
€80,000
Management effectiveness
Valuation
Price to revenue (TTM)
1,189.783
Price to book
14.71
Price to tangible book (TTM)
15.46
Price to free cash flow (TTM)
-36.832
Free cash flow yield (TTM)
-2.72%
Free cash flow per share (TTM)
-2.609
Growth
Revenue change (TTM)
-42.89%
Earnings per share change (TTM)
44.55%
3-year revenue growth (CAGR)
-11.08%
10-year revenue growth (CAGR)
30.76%
3-year earnings per share growth (CAGR)
22.68%
10-year earnings per share growth (CAGR)
12.08%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ABIVAX Société Anonyme stock?
ABIVAX Société Anonyme (ABVX) has a market cap of €7.5B as of January 29, 2026.
What is the P/E ratio for ABIVAX Société Anonyme stock?
The price to earnings (P/E) ratio for ABIVAX Société Anonyme (ABVX) stock is 0 as of January 29, 2026.
Does ABIVAX Société Anonyme stock pay dividends?
No, ABIVAX Société Anonyme (ABVX) stock does not pay dividends to its shareholders as of January 29, 2026.
When is the next ABIVAX Société Anonyme dividend payment date?
ABIVAX Société Anonyme (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for ABIVAX Société Anonyme?
ABIVAX Société Anonyme (ABVX) has a beta rating of -0.25. This means that it has an inverse relation to market volatility.